F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib

none6The disease burden in chronic myeloid leukemia (CML) is linked to the activity of its chimeric oncoprotein, the BCR-ABL1 tyrosine kinase. A recent analysis of the IRIS study showed that imatinib, the first tyrosine kinase inhibitors (TKI), resulted in impressive survival and freedom from disease progression in chronic phase patients. However, 20–30% of these patients eventually develop resistance; due largely to mutations at the ABL1 kinase domain.mixedAnthony A. Oyekunle;Fausto Castagnetti;Gabriele Gugliotta;Simona Soverini;Michele Baccarani;Gianantonio RostiAnthony A. Oyekunle;Fausto Castagnetti;Gabriele Gugliotta;Simona Soverini;Michele Baccarani;Gianantonio Rost